Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Exclusion Criteria

• •· Known contraindication or allergy to brimonidine or any of its components
• •* Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%
• •* Uncontrolled systemic disease
• •* Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.
• •* Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).
• •* Corneal abnormalities
• •* History of intraocular surgery within the last 3 months
• •* Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control
• •* Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.